Form 4: Halozyme Therapeutics SVP Mark Snyder Reports Stock Transactions

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of performance and restricted stock units, along with associated tax withholding dispositions.

Summary

• On February 16, 2025, Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, engaged in transactions involving Halozyme's common stock.
• These transactions included the vesting and settlement of 17,409 performance stock units and 4,796 restricted stock units, resulting in the acquisition of shares of common stock.
• The company withheld 9,373 and 2,582 shares, respectively, to cover tax withholding obligations related to these vestings.
• Following these transactions, Snyder directly owns 25,252 shares of Halozyme Therapeutics common stock and 9,592 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting required insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.

Stakeholder Impact

• Shareholders are informed about insider transactions, promoting transparency.
• Employees who hold similar stock-based compensation may be interested in the details of the vesting and tax implications.

Key Dates

Keywords

Form 4, Halozyme Therapeutics, Stock Options, Restricted Stock Units, Performance Stock Units, Insider Trading, Beneficial Ownership, SVP, Chief Legal Officer, HALO